Polynovo Ltd (ASX: PNV) Share Price and News

Price

$1.18

Movement

0.085 (-6.72%)

as at 13 Jun - Closed (20 mins delayed)

52 Week Range

$0.93 - $2.78

 
1 Year Return

-50.0%

Polynovo Ltd Chart and Price Data

Fundamentals Data provided by Morningstar.

Data provided by Morningstar.
Market Cap $815.19 million
P/E Ratio 155.36
Dividend Yield 0.00%
Shares Outstanding 690.84 million
Earnings per share 0.008
Dividend per share N/A
Year To Date Return -36.03%
Earnings Yield 0.64%
Franking -
Share Price

$1.18

Day Change

0.085 (-6.72%)

52 Week Range

$0.93 - $2.78

Yesterday's Close

$1.265

Today's Open

$1.265

Days Range

$1.155 - $1.265

Volume

3,105,313

Avg. Volume (1 month)

2,169,971

Turnover

$3,705,063

as at 13 Jun - Closed

  • Polynovo Ltd (ASX: PNV)
    Latest News

    A group of science or medical professionals cheering good news in the lab.
    Share Gainers

    The Polynovo (ASX:PNV) share price is up 5% on Thursday

    It has been a good day for PolyNovo's shares...

    Read more »

    sad, unhappy medical worker, medical share price fall, drop, decrease,
    Share Gainers

    Polynovo (ASX:PNV) share price flat as revenue grows 32% in FY21

    Polynovo shares are stalled after the medical devices company broke even in FY21.

    Read more »

    A doctor looks unsure, indicating share price uncertainty for ASX medical companies
    Healthcare Shares

    How did the Polynovo (ASX:PNV) share price respond last earnings season?

    The medical device company delivers its full 2021 financial year results tomorrow.

    Read more »

    Model bear in front of falling line graph, cheap stocks, cheap ASX shares
    Share Market News

    These are the 10 most shorted ASX shares

    Short sellers are targeting these ASX shares...

    Read more »

    Businessman cheering at desk with arms in the air
    Share Market News

    The Polynovo (ASX:PNV) share price is up 7% this month. Here's why

    Shares in the medical devices company are back on the up.

    Read more »

    Share Market News

    These are the 10 most shorted ASX shares

    Short sellers are targeting these ASX shares...

    Read more »

    best and worse asx shares represented by green best button and red worst button
    Healthcare Shares

    The best and worst performing ASX 200 healthcare shares of 2021

    The pandemic hasn't been a tailwind for many medical companies.

    Read more »

    most shorted shares webjet
    Share Market News

    These are the 10 most shorted ASX shares

    Short sellers are targeting these ASX shares...

    Read more »

    most shorted ASX shares
    Share Market News

    These are the 10 most shorted ASX shares

    Short sellers are targeting these ASX shares...

    Read more »

    share price dropping
    Share Fallers

    These were the worst performing ASX 200 shares in July

    These ASX 200 shares were out of form in July...

    Read more »

    surprised child reading all about asx 200 shares in a newspaper
    Share Market News

    ASX 200 Weekly Wrap: Just like that… ASX back to record highs

    What was happening on the ASX 200 last week?

    Read more »

    Young woman in yellow striped top with laptop raises arm in victory
    Share Gainers

    These were the best performing ASX 200 shares last week

    These ASX 200 shares had very strong weeks...

    Read more »

    Frequently Asked Questions

    PNV ASX Announcements

    An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.

    DateAnnouncementPrice Sensitive?TimeNo. of PagesFile Size
    21st May 2025 2025-05-21T16:21:40 Becoming a substantial holderYesNo4:21pm17695k
    16th May 2025 2025-05-16T15:06:39 Webcast Recording - Investor UpdateYesNo3:06pm1227k
    16th May 2025 2025-05-16T08:23:27 Investor Presentation & Webcast LinkYesNo8:23am7799k
    13th May 2025 2025-05-13T13:26:35 BTM delivers positive First in Man results in Cell TherapiesYesNo1:26pm4391k
    12th May 2025 2025-05-12T16:18:47 Trading HaltYesNo4:18pm2263k
    12th May 2025 2025-05-12T14:44:07 TGA Clearance for NovoSorb MTX (4 mm and 6 mm)YesNo2:44pm2226k
    7th May 2025 2025-05-07T13:28:14 PolyNovo presents at Macquarie Australia ConferenceYesNo1:28pm91.7M
    1st May 2025 2025-05-01T16:46:02 Investor Update Webinar - 16 May 2025YesNo4:46pm2279k
    22nd Apr 2025 2025-04-22T15:16:01 Change in substantial holdingYesNo3:16pm252.3M
    22nd Apr 2025 2025-04-22T08:21:59 Change in substantial holdingYesNo8:21am251.7M

    About Polynovo Ltd

    PolyNovo Ltd (ASX: PNV) develops and commercialises innovative medical devices using its patented NovoSorb technology.

    NovoSorb is a family of biocompatible polymers that are used in the treatment of burns and surgical wounds. They biodegrade into by-products that can be absorbed and excreted by the body. For example, its NovoSorb BTM (Biodegradable Temporising Matrix) can be used to temporarily close a wound and aid the body in generating new tissue.

    PolyNovo’s products are sold across Australia and New Zealand, the United States, the United Kingdom, and Europe.

    PNV Share Price History Data provided by Morningstar.

    Data provided by Morningstar.
    Date Close Change % Change Volume Open High Low
    13 Jun 2025 $1.18 $-0.09 -7.11% 3,105,313 $1.27 $1.27 $1.16
    12 Jun 2025 $1.27 $-0.04 -3.07% 2,335,785 $1.30 $1.30 $1.26
    11 Jun 2025 $1.31 $-0.04 -2.97% 2,589,203 $1.36 $1.38 $1.30
    10 Jun 2025 $1.35 $0.03 2.29% 1,829,089 $1.31 $1.35 $1.30
    06 Jun 2025 $1.31 $-0.03 -2.24% 1,082,756 $1.36 $1.36 $1.30
    05 Jun 2025 $1.34 $0.03 2.28% 2,733,737 $1.32 $1.37 $1.32
    04 Jun 2025 $1.32 $0.05 3.95% 1,389,990 $1.28 $1.34 $1.28
    03 Jun 2025 $1.27 $0.00 0.00% 1,023,591 $1.27 $1.28 $1.25
    02 Jun 2025 $1.26 $-0.05 -3.82% 1,312,053 $1.32 $1.33 $1.26
    30 May 2025 $1.31 $0.01 0.77% 1,742,811 $1.30 $1.33 $1.28
    29 May 2025 $1.31 $0.01 0.78% 740,284 $1.29 $1.32 $1.29
    28 May 2025 $1.29 $0.01 0.78% 1,633,894 $1.30 $1.33 $1.29
    27 May 2025 $1.29 $-0.02 -1.54% 2,411,210 $1.31 $1.32 $1.26
    26 May 2025 $1.30 $0.00 0.00% 1,242,079 $1.31 $1.32 $1.28
    23 May 2025 $1.31 $-0.01 -0.76% 1,507,695 $1.31 $1.32 $1.28
    22 May 2025 $1.31 $-0.05 -3.66% 2,629,588 $1.35 $1.36 $1.29
    21 May 2025 $1.37 $-0.01 -0.73% 1,816,547 $1.38 $1.41 $1.36
    20 May 2025 $1.38 $-0.06 -4.18% 3,415,741 $1.42 $1.43 $1.36
    19 May 2025 $1.44 $-0.05 -3.36% 2,163,444 $1.51 $1.53 $1.41
    16 May 2025 $1.49 $0.00 0.00% 1,911,607 $1.50 $1.53 $1.46
    15 May 2025 $1.49 $-0.02 -1.32% 2,369,534 $1.50 $1.54 $1.46

    Director Transactions Data provided by Morningstar.

    Data provided by Morningstar.
    Date Director Type Amount Value Notes
    10 Jan 2025 David Williams Sell 750 $1,522
    Off-market trade.
    30 Sep 2024 Andrew Lumsden Sell 50,000 $130,915
    On-market trade.
    26 Sep 2024 Leon Hoare Sell 100,000 $260,839
    On-market trade. As per announcement on 02-01-2024
    13 Sep 2024 Bruce Rathie Sell 750,000 $1,886,900
    On-market trade.

    Directors & Management Data provided by Morningstar.

    Data provided by Morningstar.
    Name Title Start Date Profile
    Mr David Williams Non-Executive DirectorNon-Executive Chairman Feb 2014
    Mr Williams is a director and investment banker with a track record in business development, mergers and acquisitions, and capital raising. He has experience advising companies in the food, medical device, and pharmaceutical sectors. Mr Williams is currently Managing Director of corporate advisory firm Kidder Williams.
    Dr Robyn Elliott Non-Executive Director Oct 2019
    Dr Elliott has a track record in product development, clinical trials, regulatory affairs, audits, quality management, project management and operational strategy. Her worldwide experience in new facility delivery, production scale up, strategy, regulatory affairs and audit will be invaluable to PolyNovo as the company scales its operations globally. Dr Elliott was Global Head, Strategic Portfolio Management at CSL Behring, a role that is responsible for governance oversight and business value delivery. Dr Elliott is a member of the Risk Committee.
    Mr Andrew Stuart Lumsden Non-Executive Director Jun 2021
    Mr Lumsden has more than 20 years of experience locally and internationally. Mr Lumsden is currently Chief Executive Officer of Wellcom Worldwide Australasia having previously held the roles of Group Chief Financial Officer and Group Chief Operating Officer. Prior to joining Wellcom, Mr Lumsden was a Senior Manager within the Audit and Assurance practice of PricewaterhouseCoopers. Mr Lumsden is the Chair of the Risk Committee.
    Mr Leon Hoare Non-Executive Director Jan 2016
    Mr Hoare has expertise across multiple Life Sciences sectors. He is currently the Managing Director of Lohmann & Rauscher, Australia & New Zealand (ANZ), a private EU based medical device company. Previously he was Managing Director of Smith & Nephew (S&N) ANZ. He served as President of S&N's Asia-Pacific Advanced Wound Management (AWM) businesses for 5 years and was a member of the Global Executive Management for the AWM Division.
    Ms Christine Emmanuel-Donnelly Non-Executive Director May 2020
    Ms Emmanuel-Donnelly is an IP and business development professional with more than 30 years of local and international experience. She has been on the Board of the Institute of Patent and Trademark Attorneys of Australia for over a decade. Ms Emmanuel-Donnelly was Executive Manager of Business Development and Commercial at the CSIRO, was in-house IP Counsel for Unilever in the U.K., and practiced as a patent and trademark attorney for Wilson Gunn.
    Mr Jan-Marcel Gielen Company Secretary Dec 2018
    -
    Mr Swami Raote Chief Executive Officer Jul 2022
    -
    Swami Raote Chief Executive Officer
    -
    Jan Gielen Chief Financial Officer
    -
    Philip Scorgie Chief Information Officer
    -
    Joseph Amaral Chief Medical Officer (part-time)
    -
    Ingrid Anderson Chief People Officer
    -
    David McQuillan Chief Technical and Scientific Officer
    -
    Jan-Marcel Gielen Company Secretary
    -
    David Morris President Asia Pacific
    -
    Edward Graubart President North America
    -

    Top Shareholders Data provided by Morningstar.

    Data provided by Morningstar.
    Name Shares Capital
    Hsbc Custody Nominees (Australia) Limited 96,149,727 13.93%
    J P Morgan Nominees Australia Pty Limited 80,078,534 11.60%
    Citicorp Nominees Pty Limited 37,720,578 5.46%
    Moggs Creek Pty Ltd (Moggs Creek Super A/C) 19,010,112 2.75%
    Lateral Innovations Pty Ltd (Trust A/C 10,924,103 1.58%
    Mr Anthony Shane Kittel Mrs Michele Therese Kittel (Kittel Family Super A/C) 8,050,000 1.17%
    Bnp Paribas Noms Pty Ltd 7,622,413 1.10%
    National Nominees Limited 6,653,041 0.96%
    Netwealth Investments Limited (Wrap Services A/C) 5,394,880 0.74%
    BNP Paribas Nominees Pty Ltd (IB AU Noms Retailclient) 4,533,452 0.66%
    BNP Paribas Nominees Pty Ltd (Agency Lending A/C) 4,414,903 0.64%
    Commonwealth Scientific And Industrial Research Organisation 4,081,250 0.59%
    Mrs Li-Hsien Tsai 3,955,424 0.57%
    Mr David Kenley 3,755,000 0.54%
    Mr Paul Gerard Brennan 3,569,796 0.52%
    Mr Matthew James Avery 3,439,332 0.50%
    Mr David Kenley i 3,139,855 0.45%
    Dr Marcus James Dermot Wagstaff Mrs Lara Kate Wagstaff 3,072,166 0.45%
    Mr Evan Philip Clucas Ms Leanne Jane Weston (Kuranga Nursery Super A/C) 2,931,149 0.42%
    Mr Chris Dawborn (Haskali Super Fund A/C) 2,870,271 0.42%

    Profile

    since

    Note